Lack of effect of ODQ does not exclude cGMP signalling via NO-sensitive guanylyl cyclase

British Journal of Pharmacology

Volumn 170, Issue 2, 2013, Pages 317-327

  Lies, Barbara ^a   Groneberg, Dieter ^a   Gambaryan, Stepan ^a,b   Friebe, Andreas ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b SECHENOV INSTITUTE OF EVOLUTIONARY PHYSIOLOGY AND BIOCHEMISTRY   (Russian Federation)

Author keywords

cGMP; cGMP independent effects; knockout mice; nitric oxide; NO sensitive guanylyl cyclase; ODQ; platelet; signal transduction; VASP

Indexed keywords

1H 1,2,4 OXADIAZOLO[4,3 A]QUINOXALIN 1 ONE; CYCLIC GMP; GUANYLATE CYCLASE; NITRIC OXIDE; NITRIC OXIDE SENSITIVE GUANYLYL CYCLASE; UNCLASSIFIED DRUG; VASODILATOR STIMULATED PHOSPHOPROTEIN;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; ENZYME INHIBITION; FEMALE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MALE; MOUSE; MUTANT; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SMOOTH MUSCLE RELAXATION; THROMBOCYTE; VASCULAR RING; WILD TYPE;

CGMP; CGMP-INDEPENDENT EFFECTS; KNOCKOUT MICE; NITRIC OXIDE; NO-SENSITIVE GUANYLYL CYCLASE; ODQ; PLATELET; SIGNAL TRANSDUCTION; VASP;

ADULT; ANIMALS; AORTA; CYCLIC GMP; FEMALE; GUANYLATE CYCLASE; HEK293 CELLS; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MUSCLE RELAXATION; MUSCLE, SMOOTH; NITRIC OXIDE; NITRIC OXIDE DONORS; OXADIAZOLES; OXAZINES; SIGNAL TRANSDUCTION;

EID: 84883250943     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12275     Document Type: Article

References (40)

1. Dangel O, Mergia E, Karlisch K, Groneberg D, Koesling D, Friebe A, (2010). Nitric oxide-sensitive guanylyl cyclase is the only nitric oxide receptor mediating platelet inhibition. J Thromb Haemost 8: 1343-1352.
2. Feelisch M, Kotsonis P, Siebe J, Clement B, Schmidt HH, (1999). The soluble guanylyl cyclase inhibitor 1H-[1,2,4]oxadiazolo[4,3,-a] quinoxalin-1-one is a nonselective heme protein inhibitor of nitric oxide synthase and other cytochrome P-450 enzymes involved in nitric oxide donor bioactivation. Mol Pharmacol 56: 243-253.
3. Friebe A, Koesling D, (2003). Regulation of nitric oxide-sensitive guanylyl cyclase. Circ Res 93: 96-105.
4. Friebe A, Mullershausen F, Smolenski A, Walter U, Schultz G, Koesling D, (1998). YC-1 potentiates nitric oxide- and carbon monoxide-induced cyclic GMP effects in human platelets. Mol Pharmacol 54: 962-967.
5. Friebe A, Mergia E, Dangel O, Lange A, Koesling D, (2007). Fatal gastrointestinal obstruction and hypertension in mice lacking nitric oxide-sensitive guanylyl cyclase. Proc Natl Acad Sci U S A 104: 7699-7704.
6. Gambaryan S, Kobsar A, Rukoyatkina N, Herterich S, Geiger J, Smolenski A, et al. (2010). Thrombin and collagen induce a feedback inhibitory signaling pathway in platelets involving dissociation of the catalytic subunit of protein kinase A from an NFkappaB-IkappaB complex. J Biol Chem 285: 18352-18363.
7. Garthwaite J, Southam E, Boulton CL, Nielsen EB, Schmidt K, Mayer B, (1995). Potent and selective inhibition of nitric oxide-sensitive guanylyl cyclase by 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one. Mol Pharmacol 48: 184-188.
8. Gordge MP, Hothersall JS, Noronha-Dutra AA, (1998). Evidence for a cyclic GMP-independent mechanism in the anti-platelet action of S-nitrosoglutathione. Br J Pharmacol 124: 141-148.
9. Groneberg D, Konig P, Wirth A, Offermanns S, Koesling D, Friebe A, (2010). Smooth muscle-specific deletion of nitric oxide-sensitive guanylyl cyclase is sufficient to induce hypertension in mice. Circulation 121: 401-409.
10. Groneberg D, Konig P, Koesling D, Friebe A, (2011). Nitric oxide-sensitive guanylyl cyclase is dispensable for nitrergic signaling and gut motility in mouse intestinal smooth muscle. Gastroenterology 140: 1608-1617.
11. Hess DT, Stamler JS, (2012). Regulation by S-nitrosylation of protein post-translational modification. J Biol Chem 287: 4411-4418.
12. Hofmann F, (2005). The biology of cyclic GMP-dependent protein kinases. J Biol Chem 280: 1-4.
13. Humbert P, Niroomand F, Fischer G, Mayer B, Koesling D, Hinsch KD, et al. (1990). Purification of soluble guanylyl cyclase from bovine lung by a new immunoaffinity chromatographic method. Eur J Biochem 190: 273-278.
14. Ignarro LJ, (1990). Haem-dependent activation of guanylate cyclase and cyclic GMP formation by endogenous nitric oxide: a unique transduction mechanism for transcellular signaling. Pharmacol Toxicol 67: 1-7.
15. Ignarro LJ, (2002). Nitric oxide as a unique signaling molecule in the vascular system: a historical overview. J Physiol Pharmacol 53 (4 Pt 1): 503-514.
16. Ignarro LJ, Adams JB, Horwitz PM, Wood KS, (1986). Activation of soluble guanylate cyclase by NO-hemoproteins involves NO-heme exchange. Comparison of heme-containing and heme-deficient enzyme forms. J Biol Chem 261: 4997-5002.
17. Kaupp UB, Seifert R, (2002). Cyclic nucleotide-gated ion channels. Physiol Rev 82: 769-824.
18. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). NC3Rs Reporting Guidelines Working Group. Br J Pharmacol 160: 1577-1579.
19. Lima B, Forrester MT, Hess DT, Stamler JS, (2010). S-nitrosylation in cardiovascular signaling. Circ Res 106: 633-646.
20. Luo D, Das S, Vincent SR, (1995). Effects of methylene blue and LY83583 on neuronal nitric oxide synthase and NADPH-diaphorase. Eur J Pharmacol 290: 247-251.
21. McGrath J, Drummond G, McLachlan E, Kilkenny C, Wainwright C, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
22. Marcondes S, Cardoso MH, Morganti RP, Thomazzi SM, Lilla S, Murad F, et al. (2006). Cyclic GMP-independent mechanisms contribute to the inhibition of platelet adhesion by nitric oxide donor: a role for alpha-actinin nitration. Proc Natl Acad Sci U S A 103: 3434-3439.
23. Martinez-Ruiz A, Cadenas S, Lamas S, (2011). Nitric oxide signaling: classical, less classical, and nonclassical mechanisms. Free Radic Biol Med 51: 17-29.
24. Mayer B, Brunner F, Schmidt K, (1993). Inhibition of nitric oxide synthesis by methylene blue. Biochem Pharmacol 45: 367-374.
25. Meng E, Young JS, Cha TL, Sun GH, Yu DS, Brading AF, (2012). Neuronal-derived nitric oxide modulates the activity of mouse detrusor smooth muscle. Neurourol Urodyn 31: 572-578.
26. Moncada S, Higgs EA, (1995). Molecular mechanisms and therapeutic strategies related to nitric oxide. FASEB J 9: 1319-1330.
27. Moro MA, Russel RJ, Cellek S, Lizasoain I, Su Y, Darley-Usmar VM, et al. (1996). cGMP mediates the vascular and platelet actions of nitric oxide: confirmation using an inhibitor of the soluble guanylyl cyclase. Proc Natl Acad Sci U S A 93: 1480-1485.
28. Mullershausen F, Russwurm M, Koesling D, Friebe A, (2004). In vivo reconstitution of the negative feedback in nitric oxide/cGMP signaling: role of phosphodiesterase type 5 phosphorylation. Mol Biol Cell 15: 4023-4030.
29. Mullershausen F, Lange A, Mergia E, Friebe A, Koesling D, (2006). Desensitization of NO/cGMP signaling in smooth muscle: blood vessels versus airways. Mol Pharmacol 69: 1969-1974.
30. Mulsch A, Busse R, Liebau S, Forstermann U, (1988). LY 83583 interferes with the release of endothelium-derived relaxing factor and inhibits soluble guanylate cyclase. J Pharmacol Exp Ther 247: 283-288.
31. Olesen SP, Drejer J, Axelsson O, Moldt P, Bang L, Nielsen-Kudsk JE, et al. (1998). Characterization of NS 2028 as a specific inhibitor of soluble guanylyl cyclase. Br J Pharmacol 123: 299-309.
32. Rukoyatkina N, Walter U, Friebe A, Gambaryan S, (2011). Differentiation of cGMP-dependent and -independent nitric oxide effects on platelet apoptosis and reactive oxygen species production using platelets lacking soluble guanylyl cyclase. Thromb Haemost 106: 922-933.
33. Rybalkin SD, Yan C, Bornfeldt KE, Beavo JA, (2003). Cyclic GMP phosphodiesterases and regulation of smooth muscle function. Circ Res 93: 280-291.
34. Schrammel A, Behrends S, Schmidt K, Koesling D, Mayer B, (1996). Characterization of 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one as a heme-site inhibitor of nitric oxide-sensitive guanylyl cyclase. Mol Pharmacol 50: 1-5.
35. Stasch JP, Schmidt P, Alonso-Alija C, Apeler H, Dembowsky K, Haerter M, et al. (2002). NO- and haem-independent activation of soluble guanylyl cyclase: molecular basis and cardiovascular implications of a new pharmacological principle. Br J Pharmacol 136: 773-783.
36. Stone JR, Marletta MA, (1994). Soluble guanylate cyclase from bovine lung: activation with nitric oxide and carbon monoxide and spectral characterization of the ferrous and ferric states. Biochemistry 33: 5636-5640.
37. Waldman SA, Murad F, (1987). Cyclic GMP synthesis and function. Pharmacol Rev 39: 163-196.
38. Walter U, Gambaryan S, (2004). Roles of cGMP/cGMP-dependent protein kinase in platelet activation. Blood 104: 2609.
39. Wanstall JC, Homer KL, Doggrell SA, (2005). Evidence for, and importance of, cGMP-independent mechanisms with NO and NO donors on blood vessels and platelets. Curr Vasc Pharmacol 3: 41-53.
40. Zhao Y, Brandish PE, DiValentin M, Schelvis JP, Babcock GT, Marletta MA, (2000). Inhibition of soluble guanylate cyclase by ODQ. Biochemistry 39: 10848-10854.